Abstract

Background

Low and deficient levels of vitamin A are common in low- and middle-income countries where tuberculosis burden is high. We assessed the impact of baseline levels of vitamin A and carotenoids on tuberculosis disease risk.

Methods

We conducted a case-control study nested within a longitudinal cohort of household contacts (HHCs) of pulmonary tuberculosis case patients in Lima, Peru. We defined case patients as human immunodeficiency virus (HIV)–negative HHCs with blood samples in whom tuberculosis disease developed ≥15 days after enrollment of the index patient. For each case patient, we randomly selected 4 controls from among contacts in whom tuberculosis disease did not develop, matching for sex and year of age. We used conditional logistic regression to estimate odds ratios for incident tuberculosis disease by vitamin A and carotenoids levels, controlling for other nutritional and socioeconomic factors.

Results

Among 6751 HIV-negative HHCs with baseline blood samples, 192 had secondary tuberculosis disease during follow-up. We analyzed 180 case patients with viable samples and 709 matched controls. After controlling for possible confounders, we found that baseline vitamin A deficiency was associated with a 10-fold increase in risk of tuberculosis disease among HHCs (adjusted odds ratio, 10.53; 95% confidence interval, 3.73–29.70; P < .001). This association was dose dependent, with stepwise increases in tuberculosis disease risk with each decreasing quartile of vitamin A level.

Conclusions

Vitamin A deficiency strongly predicted the risk of incident tuberculosis disease among HHCs of patients with tuberculosis. Vitamin A supplementation among individuals at high risk of tuberculosis may provide an effective means of preventing tuberculosis disease.

Although tuberculosis incidence and mortality have fallen steadily over the past 150 years in Europe and North America, tuberculosis remains one of the top global causes of death from infectious disease. The World Health Organization reported 10.4 million incident tuberculosis cases and 1.8 million associated deaths in 2015, the vast majority occurring in low- and middle-income countries [1]. In high-income countries, tuberculosis declined before the availability of either BCG vaccine or effective chemotherapy, a trend attributed to improvements in socioeconomic status [2]. Country-level data also show an inverse linear association between per capita gross domestic product and tuberculosis incidence [3] and show that a nation’s human development index strongly predicts changes in tuberculosis incidence over time [4].

Multiple lines of evidence suggest that the association between socioeconomic status and tuberculosis may be mediated through nutritional status. Studies in both humans and animals demonstrate a link between undernutrition and tuberculosis [5]. In vitro studies also provide insight into specific antimycobacterial mechanisms mediated by micronutrients [6, 7]. Although multiple studies document micronutrient deficiencies in persons with tuberculosis disease [8–10], few prospective studies have assessed preexisting nutritional status as a determinant of progression from tuberculosis infection to disease [11–15]. Notably, studies of vitamin A and tuberculosis have generally been conducted in populations at low risk for both nutritional deficits and tuberculosis, and their results have been inconclusive [14, 15].

Despite the lack of data on tuberculosis risk, multiple previous studies support the role of vitamin A in immune responses to infection. Based on studies conducted in both animals and humans, Green, Mellanby, and colleagues [16–18] first proposed in the 1920s that vitamin A is an “anti-infective” agent. Subsequently, in one of the earliest reported clinical trials, Ellison [19] showed that vitamin A supplementation reduced mortality in children with measles by 58%. Current evidence demonstrates that vitamin A deficiency (VAD) contributes to deaths from diarrheal diseases and measles, accounting for 1.7% of all deaths in children <5 years old in low- and middle-income countries [20]. In the current study, we assessed the association between baseline levels of vitamin A and carotenoids and the risk of tuberculosis disease among household contacts (HHCs) of patients with pulmonary tuberculosis in Lima, Peru.

METHODS

The study was approved by the Institutional Review Board of Harvard School of Public Health and the Research Ethics Committee of the National Institute of Health of Peru. All participants or guardians provided written informed consent.

Setting and Study Design

We conducted a case-control study nested within a prospective longitudinal cohort of HHCs of tuberculosis case patients in Lima, Peru. The study area includes approximately 3.3 million residents in urban areas and periurban, informal shantytown settlements. Between September 2009 and August 2012, we identified index patients aged ≥15 years with a diagnosis of pulmonary tuberculosis at 106 participating health centers. Within 2 weeks of enrolling an index patient, we enrolled his or her HHCs and screened them for tuberculosis disease. HHCs with symptoms were referred for sputum smear microscopy and mycobacteriology culture and treatment, according to Peru’s national guidelines [21]. HHCs aged ≤19 years and individuals with specified comorbid conditions were offered isoniazid preventive therapy (IPT).

On enrollment of HHCs, we collected the following data: age, sex, height, weight, BCG vaccination scars, IPT use, alcohol and tobacco use, self-reported diabetes mellitus, comorbid conditions (heart disease, high blood pressure, asthma, kidney disease, use of steroids or chemotherapy or immunosuppressant, and any other self-reported chronic illness), tuberculosis disease history, and housing asset information. In HHCs without prior history of tuberculosis infection or disease, we performed a tuberculin skin test (TST). We offered human immunodeficiency virus (HIV) testing and invited all HHCs to provide a venous blood sample; 60% of those ≥10 years old provided this sample.

All HHCs were evaluated for signs and symptoms of pulmonary and extrapulmonary tuberculosis disease at 2, 6, and 12 months after enrollment. We considered HHCs to have incident secondary tuberculosis disease if the diagnosis was confirmed by a health center physician >14 days after enrollment of the index patient and to have coprevalent disease if the diagnosis was earlier. We defined secondary tuberculosis disease in HHCs <18 years old according to consensus guidelines for diagnosis of tuberculosis disease in children [22].

We defined case patients as HIV-negative HHCs in whom incident secondary tuberculosis disease developed during 1 year of follow-up. We randomly selected 4 controls for each case patients from among HHCs in whom tuberculosis disease did not develop within 1 year, matching for sex and age by year.

Laboratory Methods

We stored serum samples at –80oC after collection until analysis at end of study follow-up. Laboratory personnel were unaware of the specimens’ case-control status. All samples were handled identically and assayed randomly. Levels of retinol and carotenoids (lutein + zeaxanthin, β-cryptoxanthin, total lycopene, α-carotene, and total β-carotene) were measured using high- performance liquid chromatography [23]. The interassay coefficients of variation for retinol and carotenoids were <5%. We measured levels of total 25-hydroxyvitamin D with a commercial competitive enzyme immunoassay kit (Immunodiagnostic Systems). The coefficient of variation at different levels of 25-hydroxyvitamin D ranged from 4.6% to 8.7%.

Statistical Analysis

We defined VAD as a serum retinol level <200 µg/L (<0.70 µmol/L) [24] and vitamin D deficiency, insufficiency, and sufficiency as serum 25-hydroxyvitamin D levels of <50, 50–75, and >75 nmol/L, respectively [11, 25]. We calculated body mass index (BMI) as weight in kilograms divided by square of height in meters. For children and adolescent HHCs (<20 years old), we used World Health Organization age- and sex-specific BMI z-score tables to classify those with BMI z scores below –2 as underweight and those with z score above 2 as overweight [26]. For adults (≥20 years old), we classified nutritional status as: underweight (BMI, <18.5 kg/m2), normal (18.5 to <25 kg/m2), or overweight (≥25 kg/m2). We classified HHCs as heavy drinkers if they drank ≥40 g or ≥3 alcoholic drinks daily. We derived a socioeconomic status score using principal components analysis of housing asset weighted by household size [27]. We considered HHCs to be infected with tuberculosis at baseline if they reported previous tuberculosis disease or a positive TST or had a TST result ≥10 mm at enrollment.

We constructed conditional logistic regression models to evaluate the association between quartiles of vitamin A and carotenoids levels and risk of tuberculosis disease. We performed tests for linear trend across quartiles. Multivariable-adjusted models included baseline covariates identified a priori as potential confounders and predictors of tuberculosis disease (BMI, socioeconomic status, alcohol and tobacco use, receipt of IPT, tuberculosis disease history, comorbid disease, self-reported diabetes mellitus, index patient smear status, and presence of >1 case patient in household). We also assessed the impact of VAD on incident tuberculosis disease and examined the interaction between VAD and vitamin D deficiency on tuberculosis disease risk. We stratified the final adjusted models by age. Under our method of control selection, odds ratios (ORs) approximate risk ratios because secondary tuberculosis disease was rare in this cohort [28].

In sensitivity analyses, we stratified by baseline tuberculosis infection status and separately restricted the analysis to case patients (and their matched controls) with diagnosis ≥90 days after index patient enrollment. Finally, we repeated our analyses for case patients (and their matched controls) with microbiologically confirmed tuberculosis.

RESULTS

Among 6751 HIV-negative HHCs with blood samples, tuberculosis disease developed in 258; disease was coprevalent in 66 and secondary in 192. Pulmonary disease accounted for 236 cases (91.5%), and extrapulmonary for 16 (6.2%). Of 180 secondary tuberculosis cases with viable blood samples, 147 (81.7%) were microbiologically confirmed (Figure 1). Table 1 shows baseline characteristics of case patients and controls. Case patients had lower baseline median levels of vitamin A and carotenoids than controls (Table 2). Although the pro–vitamin A carotenoids, β-cryptoxanthin, α-carotene, and β-carotene contribute to retinol levels, we found that they were not correlated with measured retinol levels (R = 0.04–0.10).

Flow diagram for nested case-control study. Abbreviations: HHCs, household contacts; HIV, human immunodeficiency virus; TB, tuberculosis.
Figure 1.

Flow diagram for nested case-control study. Abbreviations: HHCs, household contacts; HIV, human immunodeficiency virus; TB, tuberculosis.

Table 1.

Baseline Characteristics of Case Patients With Incident Tuberculosis and Matched Controls

CharacteristicNo. (%)
Case Patients (n = 180)aControls (n = 709)b
Age category
 <10 y4 (2.2)16 (2.3)
 10–19 y50 (27.8)200 (28.2)
 ≥20 y126 (70.0)493 (69.5)
Male sex94 (52.2)366 (51.6)
BMI category(n = 179)(n = 706)
 Underweight8 (4.5)6 (0.9)
 Overweight45 (25.1)299 (42.4)
 Normal126 (70.4)401 (56.8)
Socioeconomic status(n = 171)(n = 698)
 Low77 (45.0)228 (32.7)
 Middle66 (38.6)326 (46.7)
 High28 (16.4)144 (20.6)
Heavy alcohol use14 (8.1) (n = 174)64 (9.3) (n = 692)
Current smoking13 (7.4) (n = 176)78 (11.2) (n = 699)
Self-reported diabetes6 (3.4) (n = 179)11 (1.6) (n = 701)
Comorbid disease37 (20.6)175 (24.7)
Isoniazid preventive therapy7 (3.9)108 (15.2)
BCG vaccine scar159 (88.3)628 (88.6)
History of tuberculosis34 (18.9)55 (7.8) (n = 708)
Tuberculosis infection at baseline145 (82.4) (n = 176)281 (41.1) (n = 683)
 Smear positive156 (86.7)486 (68.7) (n = 707)
 Cavitary disease54 (30.2) (n = 179)175 (25.1) (n = 697)
CharacteristicNo. (%)
Case Patients (n = 180)aControls (n = 709)b
Age category
 <10 y4 (2.2)16 (2.3)
 10–19 y50 (27.8)200 (28.2)
 ≥20 y126 (70.0)493 (69.5)
Male sex94 (52.2)366 (51.6)
BMI category(n = 179)(n = 706)
 Underweight8 (4.5)6 (0.9)
 Overweight45 (25.1)299 (42.4)
 Normal126 (70.4)401 (56.8)
Socioeconomic status(n = 171)(n = 698)
 Low77 (45.0)228 (32.7)
 Middle66 (38.6)326 (46.7)
 High28 (16.4)144 (20.6)
Heavy alcohol use14 (8.1) (n = 174)64 (9.3) (n = 692)
Current smoking13 (7.4) (n = 176)78 (11.2) (n = 699)
Self-reported diabetes6 (3.4) (n = 179)11 (1.6) (n = 701)
Comorbid disease37 (20.6)175 (24.7)
Isoniazid preventive therapy7 (3.9)108 (15.2)
BCG vaccine scar159 (88.3)628 (88.6)
History of tuberculosis34 (18.9)55 (7.8) (n = 708)
Tuberculosis infection at baseline145 (82.4) (n = 176)281 (41.1) (n = 683)
 Smear positive156 (86.7)486 (68.7) (n = 707)
 Cavitary disease54 (30.2) (n = 179)175 (25.1) (n = 697)

Abbreviation: BMI, body mass index; BCG, Bacillus Calmette-Guerin.

aData available in 180 case patients except where noted otherwise.

bData available in 709 controls except where noted otherwise.

Table 1.

Baseline Characteristics of Case Patients With Incident Tuberculosis and Matched Controls

CharacteristicNo. (%)
Case Patients (n = 180)aControls (n = 709)b
Age category
 <10 y4 (2.2)16 (2.3)
 10–19 y50 (27.8)200 (28.2)
 ≥20 y126 (70.0)493 (69.5)
Male sex94 (52.2)366 (51.6)
BMI category(n = 179)(n = 706)
 Underweight8 (4.5)6 (0.9)
 Overweight45 (25.1)299 (42.4)
 Normal126 (70.4)401 (56.8)
Socioeconomic status(n = 171)(n = 698)
 Low77 (45.0)228 (32.7)
 Middle66 (38.6)326 (46.7)
 High28 (16.4)144 (20.6)
Heavy alcohol use14 (8.1) (n = 174)64 (9.3) (n = 692)
Current smoking13 (7.4) (n = 176)78 (11.2) (n = 699)
Self-reported diabetes6 (3.4) (n = 179)11 (1.6) (n = 701)
Comorbid disease37 (20.6)175 (24.7)
Isoniazid preventive therapy7 (3.9)108 (15.2)
BCG vaccine scar159 (88.3)628 (88.6)
History of tuberculosis34 (18.9)55 (7.8) (n = 708)
Tuberculosis infection at baseline145 (82.4) (n = 176)281 (41.1) (n = 683)
 Smear positive156 (86.7)486 (68.7) (n = 707)
 Cavitary disease54 (30.2) (n = 179)175 (25.1) (n = 697)
CharacteristicNo. (%)
Case Patients (n = 180)aControls (n = 709)b
Age category
 <10 y4 (2.2)16 (2.3)
 10–19 y50 (27.8)200 (28.2)
 ≥20 y126 (70.0)493 (69.5)
Male sex94 (52.2)366 (51.6)
BMI category(n = 179)(n = 706)
 Underweight8 (4.5)6 (0.9)
 Overweight45 (25.1)299 (42.4)
 Normal126 (70.4)401 (56.8)
Socioeconomic status(n = 171)(n = 698)
 Low77 (45.0)228 (32.7)
 Middle66 (38.6)326 (46.7)
 High28 (16.4)144 (20.6)
Heavy alcohol use14 (8.1) (n = 174)64 (9.3) (n = 692)
Current smoking13 (7.4) (n = 176)78 (11.2) (n = 699)
Self-reported diabetes6 (3.4) (n = 179)11 (1.6) (n = 701)
Comorbid disease37 (20.6)175 (24.7)
Isoniazid preventive therapy7 (3.9)108 (15.2)
BCG vaccine scar159 (88.3)628 (88.6)
History of tuberculosis34 (18.9)55 (7.8) (n = 708)
Tuberculosis infection at baseline145 (82.4) (n = 176)281 (41.1) (n = 683)
 Smear positive156 (86.7)486 (68.7) (n = 707)
 Cavitary disease54 (30.2) (n = 179)175 (25.1) (n = 697)

Abbreviation: BMI, body mass index; BCG, Bacillus Calmette-Guerin.

aData available in 180 case patients except where noted otherwise.

bData available in 709 controls except where noted otherwise.

Table 2.

Baseline Levels of Micronutrients Among Case Patients and Controls

MicronutrientMedian Level (IQR)aP Valueb
Case Patients (n = 180)Controls (n = 709)
Vitamin A, µg/L316.5 (250.5–381.4)373.6 (310.4–460.2)<.001
Vitamin A deficient (<200 µg/L), No. (%)24 (13.3)16 (2.3)<.001
25-hydroxyvitamin vitamin D, nmol/L53.9 (42.7–64.0)54.7 (44.5–67.1)>.99
Vitamin D category, No. (%)
 Deficient (<50 nmol/L)76 (42.2)259 (36.5).13
 Insufficient (50–75 nmol/L)84 (46.7)348 (49.1).45
 Sufficient (>75 nmol/L)20 (11.1)102 (14.4)Reference
Lutein + zeaxanthin, µg/L150.5 (111.1–186.1)153.6 (121.5–201.8).02
β-cryptoxanthin, µg/L107.3 (68.2–196.7)142.3 (85.5–240.5).04
Total lycopene, µg/L99.7 (64.9–147.3)112.9 (77.6–164.5).03
α-Carotene, µg/L65.3 (44.2–97.1)75.8 (52.6–110.0).04
Total β-carotene, µg/L123.2 (67.9–192.4)138.0 (86.3–216.4).07
MicronutrientMedian Level (IQR)aP Valueb
Case Patients (n = 180)Controls (n = 709)
Vitamin A, µg/L316.5 (250.5–381.4)373.6 (310.4–460.2)<.001
Vitamin A deficient (<200 µg/L), No. (%)24 (13.3)16 (2.3)<.001
25-hydroxyvitamin vitamin D, nmol/L53.9 (42.7–64.0)54.7 (44.5–67.1)>.99
Vitamin D category, No. (%)
 Deficient (<50 nmol/L)76 (42.2)259 (36.5).13
 Insufficient (50–75 nmol/L)84 (46.7)348 (49.1).45
 Sufficient (>75 nmol/L)20 (11.1)102 (14.4)Reference
Lutein + zeaxanthin, µg/L150.5 (111.1–186.1)153.6 (121.5–201.8).02
β-cryptoxanthin, µg/L107.3 (68.2–196.7)142.3 (85.5–240.5).04
Total lycopene, µg/L99.7 (64.9–147.3)112.9 (77.6–164.5).03
α-Carotene, µg/L65.3 (44.2–97.1)75.8 (52.6–110.0).04
Total β-carotene, µg/L123.2 (67.9–192.4)138.0 (86.3–216.4).07

Abbreviation: IQR, interquartile range.

aData represent median level (IQR) unless otherwise specified as No. (%).

bUnivariate P values adjusted for matching factors (age and sex).

Table 2.

Baseline Levels of Micronutrients Among Case Patients and Controls

MicronutrientMedian Level (IQR)aP Valueb
Case Patients (n = 180)Controls (n = 709)
Vitamin A, µg/L316.5 (250.5–381.4)373.6 (310.4–460.2)<.001
Vitamin A deficient (<200 µg/L), No. (%)24 (13.3)16 (2.3)<.001
25-hydroxyvitamin vitamin D, nmol/L53.9 (42.7–64.0)54.7 (44.5–67.1)>.99
Vitamin D category, No. (%)
 Deficient (<50 nmol/L)76 (42.2)259 (36.5).13
 Insufficient (50–75 nmol/L)84 (46.7)348 (49.1).45
 Sufficient (>75 nmol/L)20 (11.1)102 (14.4)Reference
Lutein + zeaxanthin, µg/L150.5 (111.1–186.1)153.6 (121.5–201.8).02
β-cryptoxanthin, µg/L107.3 (68.2–196.7)142.3 (85.5–240.5).04
Total lycopene, µg/L99.7 (64.9–147.3)112.9 (77.6–164.5).03
α-Carotene, µg/L65.3 (44.2–97.1)75.8 (52.6–110.0).04
Total β-carotene, µg/L123.2 (67.9–192.4)138.0 (86.3–216.4).07
MicronutrientMedian Level (IQR)aP Valueb
Case Patients (n = 180)Controls (n = 709)
Vitamin A, µg/L316.5 (250.5–381.4)373.6 (310.4–460.2)<.001
Vitamin A deficient (<200 µg/L), No. (%)24 (13.3)16 (2.3)<.001
25-hydroxyvitamin vitamin D, nmol/L53.9 (42.7–64.0)54.7 (44.5–67.1)>.99
Vitamin D category, No. (%)
 Deficient (<50 nmol/L)76 (42.2)259 (36.5).13
 Insufficient (50–75 nmol/L)84 (46.7)348 (49.1).45
 Sufficient (>75 nmol/L)20 (11.1)102 (14.4)Reference
Lutein + zeaxanthin, µg/L150.5 (111.1–186.1)153.6 (121.5–201.8).02
β-cryptoxanthin, µg/L107.3 (68.2–196.7)142.3 (85.5–240.5).04
Total lycopene, µg/L99.7 (64.9–147.3)112.9 (77.6–164.5).03
α-Carotene, µg/L65.3 (44.2–97.1)75.8 (52.6–110.0).04
Total β-carotene, µg/L123.2 (67.9–192.4)138.0 (86.3–216.4).07

Abbreviation: IQR, interquartile range.

aData represent median level (IQR) unless otherwise specified as No. (%).

bUnivariate P values adjusted for matching factors (age and sex).

Table 3 demonstrates significant univariate associations between incident tuberculosis disease and baseline quartiles of vitamin A, lutein + zeaxanthin, β-cryptoxanthin, total lycopene, and α-carotene levels. After multivariable adjustment for matching factors and confounders, HHCs in the lowest quartile of vitamin A levels had 6 times the risk of tuberculosis disease of those in the highest quartile (OR, 6.38; 95% confidence interval [CI], 2.82–14.46; P for trend < .001) [Table 3]. Lower levels of β-cryptoxanthin (OR for lowest vs highest quartile, 2.75; 95% CI, 1.42–5.33; P for trend = .003) were also associated with increased risk of tuberculosis disease.

Table 3.

Micronutrient Levels by Quartile and the Risk of Tuberculosis Disease among Household Contacts of Index Tuberculosis Case Patients (n = 889)

MicronutrientQuartiles of Micronutrient LevelP Value for Trend
Quartile 1 (Lowest)Quartile 2Quartile 3Quartile 4 (Highest)
Vitamin A
 Case patients/controls, No.76/14645/17741/18218/204
 Median level (range), µg/L258.0 (53.1–296.2)332.1 (297.5–363.8)396.5 (363.8–441.7)510.4 (441.7–929.9)
 Univariate OR (95% CI)9.34 (4.98–17.51)4.22 (2.24–7.96)3.02 (1.65–5.53)1.00<.001
 Multivariate ORa (95% CI)6.38 (2.82–14.46)3.57 (1.60–7.96)2.95 (1.34–6.51)1.00<.001
Lutein + zeaxanthin
 Case patients/controls, No.56/16640/18252/17132/190
 Median level (range), µg/L98.0 (25.8–119.2)135.5 (119.3–153.1)174.5 (153.2–196.2)243.2 (196.7–529.9)
 Univariate OR (95% CI)2.03 (1.25–3.29)1.33 (.80–2.23)1.84 (1.13–3.01)1.00.01
 Multivariate ORa (95% CI)1.99 (1.08–3.66)0.85 (.44–1.66)2.06 (1.10–3.87)1.00.14
β-Cryptoxanthin
 Case patients/controls, No.61/16148/17437/18634/188
 Median level (range), µg/L60.8 (3.9–81.2)103.9 (81.6–132.6)171.8 (132.6–228.2)339.7 (228.5–1778.4)
 Univariate OR (95% CI)2.17 (1.33–3.53)1.57 (.94–2.62)1.14 (.68–1.91)1.00.002
 Multivariate ORa (95% CI)2.75 (1.42–5.33)1.96 (1.02–3.77)1.63 (.82–3.22)1.00.003
Total lycopene
 Median level (range), µg/L55.8 (5.4–75.0)89.4 (75.0–108.7)133.0 (108.8–160.7)209.4 (162.0–724.5)
 Case patients/controls, No.56/16647/17539/18438/184
 Univariate OR (95% CI)1.64 (1.04–2.60)1.30 (.81–2.09)1.03 (.63–1.68)1.00.03
 Multivariate ORa (95% CI)1.47 (.83–2.61)1.27 (.71–2.27)0.97 (.53–1.80)1.00.17
α-Carotene
 Median level (range), µg/L39.1 (4.2–51.7)62.3 (51.7–73.3)89.1 (73.3–107.7)144.6 (108.1–1282.8)
 Case patients/controls, No.53/16953/16938/18536/186
 Univariate OR (95% CI)1.65 (1.02–2.65)1.64 (1.01–2.64)1.06 (.64–1.76)1.00.02
 Multivariate ORa (95% CI)1.58 (.86–2.91)1.70 (.93–3.10)1.06 (.55–2.03)1.00.06
Total β-carotene
 Median level (range), µg/L56.4 (4.8–84.7)108.2 (84.8–136.4)162.1 (136.5–212.1)305.9 (212.4–1452.1)
 Case patients/controls, No.54/16842/18044/17940/182
 Univariate OR (95% CI)1.51 (.94–2.44)1.07 (.66–1.75)1.15 (.71–1.85)1.00.16
 Multivariate ORa (95% CI)1.59 (.86–2.93)1.28 (.70–2.34)1.21 (.65–2.26)1.00.15
MicronutrientQuartiles of Micronutrient LevelP Value for Trend
Quartile 1 (Lowest)Quartile 2Quartile 3Quartile 4 (Highest)
Vitamin A
 Case patients/controls, No.76/14645/17741/18218/204
 Median level (range), µg/L258.0 (53.1–296.2)332.1 (297.5–363.8)396.5 (363.8–441.7)510.4 (441.7–929.9)
 Univariate OR (95% CI)9.34 (4.98–17.51)4.22 (2.24–7.96)3.02 (1.65–5.53)1.00<.001
 Multivariate ORa (95% CI)6.38 (2.82–14.46)3.57 (1.60–7.96)2.95 (1.34–6.51)1.00<.001
Lutein + zeaxanthin
 Case patients/controls, No.56/16640/18252/17132/190
 Median level (range), µg/L98.0 (25.8–119.2)135.5 (119.3–153.1)174.5 (153.2–196.2)243.2 (196.7–529.9)
 Univariate OR (95% CI)2.03 (1.25–3.29)1.33 (.80–2.23)1.84 (1.13–3.01)1.00.01
 Multivariate ORa (95% CI)1.99 (1.08–3.66)0.85 (.44–1.66)2.06 (1.10–3.87)1.00.14
β-Cryptoxanthin
 Case patients/controls, No.61/16148/17437/18634/188
 Median level (range), µg/L60.8 (3.9–81.2)103.9 (81.6–132.6)171.8 (132.6–228.2)339.7 (228.5–1778.4)
 Univariate OR (95% CI)2.17 (1.33–3.53)1.57 (.94–2.62)1.14 (.68–1.91)1.00.002
 Multivariate ORa (95% CI)2.75 (1.42–5.33)1.96 (1.02–3.77)1.63 (.82–3.22)1.00.003
Total lycopene
 Median level (range), µg/L55.8 (5.4–75.0)89.4 (75.0–108.7)133.0 (108.8–160.7)209.4 (162.0–724.5)
 Case patients/controls, No.56/16647/17539/18438/184
 Univariate OR (95% CI)1.64 (1.04–2.60)1.30 (.81–2.09)1.03 (.63–1.68)1.00.03
 Multivariate ORa (95% CI)1.47 (.83–2.61)1.27 (.71–2.27)0.97 (.53–1.80)1.00.17
α-Carotene
 Median level (range), µg/L39.1 (4.2–51.7)62.3 (51.7–73.3)89.1 (73.3–107.7)144.6 (108.1–1282.8)
 Case patients/controls, No.53/16953/16938/18536/186
 Univariate OR (95% CI)1.65 (1.02–2.65)1.64 (1.01–2.64)1.06 (.64–1.76)1.00.02
 Multivariate ORa (95% CI)1.58 (.86–2.91)1.70 (.93–3.10)1.06 (.55–2.03)1.00.06
Total β-carotene
 Median level (range), µg/L56.4 (4.8–84.7)108.2 (84.8–136.4)162.1 (136.5–212.1)305.9 (212.4–1452.1)
 Case patients/controls, No.54/16842/18044/17940/182
 Univariate OR (95% CI)1.51 (.94–2.44)1.07 (.66–1.75)1.15 (.71–1.85)1.00.16
 Multivariate ORa (95% CI)1.59 (.86–2.93)1.28 (.70–2.34)1.21 (.65–2.26)1.00.15

Abbreviations: CI, confidence interval; OR, odds ratio.

aAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, index patient smear status, and presence of >1 tuberculosis case in household.

Table 3.

Micronutrient Levels by Quartile and the Risk of Tuberculosis Disease among Household Contacts of Index Tuberculosis Case Patients (n = 889)

MicronutrientQuartiles of Micronutrient LevelP Value for Trend
Quartile 1 (Lowest)Quartile 2Quartile 3Quartile 4 (Highest)
Vitamin A
 Case patients/controls, No.76/14645/17741/18218/204
 Median level (range), µg/L258.0 (53.1–296.2)332.1 (297.5–363.8)396.5 (363.8–441.7)510.4 (441.7–929.9)
 Univariate OR (95% CI)9.34 (4.98–17.51)4.22 (2.24–7.96)3.02 (1.65–5.53)1.00<.001
 Multivariate ORa (95% CI)6.38 (2.82–14.46)3.57 (1.60–7.96)2.95 (1.34–6.51)1.00<.001
Lutein + zeaxanthin
 Case patients/controls, No.56/16640/18252/17132/190
 Median level (range), µg/L98.0 (25.8–119.2)135.5 (119.3–153.1)174.5 (153.2–196.2)243.2 (196.7–529.9)
 Univariate OR (95% CI)2.03 (1.25–3.29)1.33 (.80–2.23)1.84 (1.13–3.01)1.00.01
 Multivariate ORa (95% CI)1.99 (1.08–3.66)0.85 (.44–1.66)2.06 (1.10–3.87)1.00.14
β-Cryptoxanthin
 Case patients/controls, No.61/16148/17437/18634/188
 Median level (range), µg/L60.8 (3.9–81.2)103.9 (81.6–132.6)171.8 (132.6–228.2)339.7 (228.5–1778.4)
 Univariate OR (95% CI)2.17 (1.33–3.53)1.57 (.94–2.62)1.14 (.68–1.91)1.00.002
 Multivariate ORa (95% CI)2.75 (1.42–5.33)1.96 (1.02–3.77)1.63 (.82–3.22)1.00.003
Total lycopene
 Median level (range), µg/L55.8 (5.4–75.0)89.4 (75.0–108.7)133.0 (108.8–160.7)209.4 (162.0–724.5)
 Case patients/controls, No.56/16647/17539/18438/184
 Univariate OR (95% CI)1.64 (1.04–2.60)1.30 (.81–2.09)1.03 (.63–1.68)1.00.03
 Multivariate ORa (95% CI)1.47 (.83–2.61)1.27 (.71–2.27)0.97 (.53–1.80)1.00.17
α-Carotene
 Median level (range), µg/L39.1 (4.2–51.7)62.3 (51.7–73.3)89.1 (73.3–107.7)144.6 (108.1–1282.8)
 Case patients/controls, No.53/16953/16938/18536/186
 Univariate OR (95% CI)1.65 (1.02–2.65)1.64 (1.01–2.64)1.06 (.64–1.76)1.00.02
 Multivariate ORa (95% CI)1.58 (.86–2.91)1.70 (.93–3.10)1.06 (.55–2.03)1.00.06
Total β-carotene
 Median level (range), µg/L56.4 (4.8–84.7)108.2 (84.8–136.4)162.1 (136.5–212.1)305.9 (212.4–1452.1)
 Case patients/controls, No.54/16842/18044/17940/182
 Univariate OR (95% CI)1.51 (.94–2.44)1.07 (.66–1.75)1.15 (.71–1.85)1.00.16
 Multivariate ORa (95% CI)1.59 (.86–2.93)1.28 (.70–2.34)1.21 (.65–2.26)1.00.15
MicronutrientQuartiles of Micronutrient LevelP Value for Trend
Quartile 1 (Lowest)Quartile 2Quartile 3Quartile 4 (Highest)
Vitamin A
 Case patients/controls, No.76/14645/17741/18218/204
 Median level (range), µg/L258.0 (53.1–296.2)332.1 (297.5–363.8)396.5 (363.8–441.7)510.4 (441.7–929.9)
 Univariate OR (95% CI)9.34 (4.98–17.51)4.22 (2.24–7.96)3.02 (1.65–5.53)1.00<.001
 Multivariate ORa (95% CI)6.38 (2.82–14.46)3.57 (1.60–7.96)2.95 (1.34–6.51)1.00<.001
Lutein + zeaxanthin
 Case patients/controls, No.56/16640/18252/17132/190
 Median level (range), µg/L98.0 (25.8–119.2)135.5 (119.3–153.1)174.5 (153.2–196.2)243.2 (196.7–529.9)
 Univariate OR (95% CI)2.03 (1.25–3.29)1.33 (.80–2.23)1.84 (1.13–3.01)1.00.01
 Multivariate ORa (95% CI)1.99 (1.08–3.66)0.85 (.44–1.66)2.06 (1.10–3.87)1.00.14
β-Cryptoxanthin
 Case patients/controls, No.61/16148/17437/18634/188
 Median level (range), µg/L60.8 (3.9–81.2)103.9 (81.6–132.6)171.8 (132.6–228.2)339.7 (228.5–1778.4)
 Univariate OR (95% CI)2.17 (1.33–3.53)1.57 (.94–2.62)1.14 (.68–1.91)1.00.002
 Multivariate ORa (95% CI)2.75 (1.42–5.33)1.96 (1.02–3.77)1.63 (.82–3.22)1.00.003
Total lycopene
 Median level (range), µg/L55.8 (5.4–75.0)89.4 (75.0–108.7)133.0 (108.8–160.7)209.4 (162.0–724.5)
 Case patients/controls, No.56/16647/17539/18438/184
 Univariate OR (95% CI)1.64 (1.04–2.60)1.30 (.81–2.09)1.03 (.63–1.68)1.00.03
 Multivariate ORa (95% CI)1.47 (.83–2.61)1.27 (.71–2.27)0.97 (.53–1.80)1.00.17
α-Carotene
 Median level (range), µg/L39.1 (4.2–51.7)62.3 (51.7–73.3)89.1 (73.3–107.7)144.6 (108.1–1282.8)
 Case patients/controls, No.53/16953/16938/18536/186
 Univariate OR (95% CI)1.65 (1.02–2.65)1.64 (1.01–2.64)1.06 (.64–1.76)1.00.02
 Multivariate ORa (95% CI)1.58 (.86–2.91)1.70 (.93–3.10)1.06 (.55–2.03)1.00.06
Total β-carotene
 Median level (range), µg/L56.4 (4.8–84.7)108.2 (84.8–136.4)162.1 (136.5–212.1)305.9 (212.4–1452.1)
 Case patients/controls, No.54/16842/18044/17940/182
 Univariate OR (95% CI)1.51 (.94–2.44)1.07 (.66–1.75)1.15 (.71–1.85)1.00.16
 Multivariate ORa (95% CI)1.59 (.86–2.93)1.28 (.70–2.34)1.21 (.65–2.26)1.00.15

Abbreviations: CI, confidence interval; OR, odds ratio.

aAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, index patient smear status, and presence of >1 tuberculosis case in household.

Table 4 provides univariate and adjusted ORs for VAD. HHCs with baseline VAD had 10.53-fold increased risk of incident tuberculosis disease (95% CI, 3.73–29.70; P < .001). Results of a statistical test for interaction between vitamins A and D deficiencies were not significant (P for interaction = .24; Table 5).

Table 4.

Association between Baseline Characteristics and Risk of Tuberculosis Disease

CharacteristicUnivariate OR (95% CI) (n = 889)P ValueMultivariate ORb (95% CI) (n = 822)P Value
BMI categories (n = 885)a
 Underweight4.14 (1.32–12.94).012.37 (.30–18.48).41
 Overweight0.39 (.26–.60)<.0010.37 (.22–.62)<.001
 Normal1.001.00
Socioeconomic status (n = 869)
 Low1.69 (1.16–2.47).011.61 (.98–2.64).06
 Middle1.001.00
 High0.95 (.59–1.55).851.13 (.62–2.07).68
Heavy alcohol use (n = 866)0.83 (.45–1.45).550.76 (.31–1.88).56
Current smoking (n = 875)0.62 (.33–1.15).130.77 (.35–1.70).52
Isoniazid preventive therapy0.16 (.07–.39)<.0010.14 (.05–.42).001
History of tuberculosis (n = 888)2.89 (1.78–4.70)<.0012.11 (1.07–4.18).03
Comorbid disease0.78 (.51–1.18).230.93 (.54–1.59).79
Self-reported diabetes mellitus (n = 880)2.38 (.83–6.84).113.13 (.80–12.17).10
Index patient smear positive (n = 887)2.96 (1.87–4.69)<.0012.98 (1.66–5.37)<.001
VAD (level <200 µg/L)7.65 (3.72–15.71)<.00110.53 (3.73–29.70)<.001
CharacteristicUnivariate OR (95% CI) (n = 889)P ValueMultivariate ORb (95% CI) (n = 822)P Value
BMI categories (n = 885)a
 Underweight4.14 (1.32–12.94).012.37 (.30–18.48).41
 Overweight0.39 (.26–.60)<.0010.37 (.22–.62)<.001
 Normal1.001.00
Socioeconomic status (n = 869)
 Low1.69 (1.16–2.47).011.61 (.98–2.64).06
 Middle1.001.00
 High0.95 (.59–1.55).851.13 (.62–2.07).68
Heavy alcohol use (n = 866)0.83 (.45–1.45).550.76 (.31–1.88).56
Current smoking (n = 875)0.62 (.33–1.15).130.77 (.35–1.70).52
Isoniazid preventive therapy0.16 (.07–.39)<.0010.14 (.05–.42).001
History of tuberculosis (n = 888)2.89 (1.78–4.70)<.0012.11 (1.07–4.18).03
Comorbid disease0.78 (.51–1.18).230.93 (.54–1.59).79
Self-reported diabetes mellitus (n = 880)2.38 (.83–6.84).113.13 (.80–12.17).10
Index patient smear positive (n = 887)2.96 (1.87–4.69)<.0012.98 (1.66–5.37)<.001
VAD (level <200 µg/L)7.65 (3.72–15.71)<.00110.53 (3.73–29.70)<.001

Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; VAD, vitamin A deficiency.

aSample sizes represent total number of subjects with data for corresponding variable, otherwise sample size is 889.

bAdjusted for matching factors (age and sex), vitamin D levels, BMI categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, index patient smear status, and presence of >1 tuberculosis case in household.

Table 4.

Association between Baseline Characteristics and Risk of Tuberculosis Disease

CharacteristicUnivariate OR (95% CI) (n = 889)P ValueMultivariate ORb (95% CI) (n = 822)P Value
BMI categories (n = 885)a
 Underweight4.14 (1.32–12.94).012.37 (.30–18.48).41
 Overweight0.39 (.26–.60)<.0010.37 (.22–.62)<.001
 Normal1.001.00
Socioeconomic status (n = 869)
 Low1.69 (1.16–2.47).011.61 (.98–2.64).06
 Middle1.001.00
 High0.95 (.59–1.55).851.13 (.62–2.07).68
Heavy alcohol use (n = 866)0.83 (.45–1.45).550.76 (.31–1.88).56
Current smoking (n = 875)0.62 (.33–1.15).130.77 (.35–1.70).52
Isoniazid preventive therapy0.16 (.07–.39)<.0010.14 (.05–.42).001
History of tuberculosis (n = 888)2.89 (1.78–4.70)<.0012.11 (1.07–4.18).03
Comorbid disease0.78 (.51–1.18).230.93 (.54–1.59).79
Self-reported diabetes mellitus (n = 880)2.38 (.83–6.84).113.13 (.80–12.17).10
Index patient smear positive (n = 887)2.96 (1.87–4.69)<.0012.98 (1.66–5.37)<.001
VAD (level <200 µg/L)7.65 (3.72–15.71)<.00110.53 (3.73–29.70)<.001
CharacteristicUnivariate OR (95% CI) (n = 889)P ValueMultivariate ORb (95% CI) (n = 822)P Value
BMI categories (n = 885)a
 Underweight4.14 (1.32–12.94).012.37 (.30–18.48).41
 Overweight0.39 (.26–.60)<.0010.37 (.22–.62)<.001
 Normal1.001.00
Socioeconomic status (n = 869)
 Low1.69 (1.16–2.47).011.61 (.98–2.64).06
 Middle1.001.00
 High0.95 (.59–1.55).851.13 (.62–2.07).68
Heavy alcohol use (n = 866)0.83 (.45–1.45).550.76 (.31–1.88).56
Current smoking (n = 875)0.62 (.33–1.15).130.77 (.35–1.70).52
Isoniazid preventive therapy0.16 (.07–.39)<.0010.14 (.05–.42).001
History of tuberculosis (n = 888)2.89 (1.78–4.70)<.0012.11 (1.07–4.18).03
Comorbid disease0.78 (.51–1.18).230.93 (.54–1.59).79
Self-reported diabetes mellitus (n = 880)2.38 (.83–6.84).113.13 (.80–12.17).10
Index patient smear positive (n = 887)2.96 (1.87–4.69)<.0012.98 (1.66–5.37)<.001
VAD (level <200 µg/L)7.65 (3.72–15.71)<.00110.53 (3.73–29.70)<.001

Abbreviations: BMI, body mass index; CI, confidence interval; OR, odds ratio; VAD, vitamin A deficiency.

aSample sizes represent total number of subjects with data for corresponding variable, otherwise sample size is 889.

bAdjusted for matching factors (age and sex), vitamin D levels, BMI categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, index patient smear status, and presence of >1 tuberculosis case in household.

Table 5.

Interaction Between Vitamin A and Vitamin D Levels for Risk of Tuberculosis Disease

Vitamin A and D LevelsCase Patients, No./Controls, No.Multivariate OR (95% CI)aP Value b
Both VAD and VDD12/96.38 (1.77–22.97)c.005
VAD without VDD12/724.04 (3.96–145.90)d<.001
No VAD or VDD92/4431.00
Vitamin A and D LevelsCase Patients, No./Controls, No.Multivariate OR (95% CI)aP Value b
Both VAD and VDD12/96.38 (1.77–22.97)c.005
VAD without VDD12/724.04 (3.96–145.90)d<.001
No VAD or VDD92/4431.00

Abbreviations: CI, confidence interval; OR, odds ratio; VAD, vitamin A deficiency; VDD, vitamin D deficiency.

aAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, index patient smear status, and presence of >1 tuberculosis case in household.

bP value for interaction = .24

cOR for VAD among household contacts with VDD.

dOR for VAD among household contacts without VDD.

Table 5.

Interaction Between Vitamin A and Vitamin D Levels for Risk of Tuberculosis Disease

Vitamin A and D LevelsCase Patients, No./Controls, No.Multivariate OR (95% CI)aP Value b
Both VAD and VDD12/96.38 (1.77–22.97)c.005
VAD without VDD12/724.04 (3.96–145.90)d<.001
No VAD or VDD92/4431.00
Vitamin A and D LevelsCase Patients, No./Controls, No.Multivariate OR (95% CI)aP Value b
Both VAD and VDD12/96.38 (1.77–22.97)c.005
VAD without VDD12/724.04 (3.96–145.90)d<.001
No VAD or VDD92/4431.00

Abbreviations: CI, confidence interval; OR, odds ratio; VAD, vitamin A deficiency; VDD, vitamin D deficiency.

aAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, index patient smear status, and presence of >1 tuberculosis case in household.

bP value for interaction = .24

cOR for VAD among household contacts with VDD.

dOR for VAD among household contacts without VDD.

Stratification by age showed that VAD increased the risk of tuberculosis disease nearly 20-fold in 10–19-year-olds (adjusted OR, 18.58; 95% CI, 3.54–97.60; P = .001) and 10-fold in those aged ≥20 years (10.21; 2.43–42.91; P = .002) [Table 6]. Adolescents (aged 10–19 years) in the lowest quartile of carotenoid levels were at higher risk for tuberculosis disease, but there was no effect in older HHCs.

Table 6.

Micronutrient Levels and Risk of Tuberculosis Disease Stratified by Age Category

Micronutrient Levels by QuartileaAge 10–19 yAge ≥ 20 y
Multivariate ORb (95% CI) (n = 237)P ValueMultivariate ORb (95% CI) (n = 565)P Value
Vitamin A <200 µg/L18.58 (3.54–97.60).00110.21 (2.43–42.91).002
Vitamin A level
 Quartile 17.72 (2.06–28.91).0024.43 (1.83–10.73).001
 Quartile 24.83 (1.23–18.92).023.50 (1.46–8.40).005
 Quartile 31.001.65 (.70–3.88).25
 Quartile 4NAc1.00
P value for trend.003<.001
Lutein + zeaxanthin
 Quartile 11.68 (.59–4.76).331.61 (.78–3.31).19
 Quartile 21.09 (.37–3.20).881.41 (.67–2.96).37
 Quartile 30.33 (.08–1.33).122.05 (1.01–4.17).05
 Quartile 41.001.00
P value for trend.12.24
β-Cryptoxanthin
 Quartile 14.39 (1.33–14.46).012.00 (.95–4.25).07
 Quartile 21.57 (.46–5.34).472.02 (1.00–4.08).05
 Quartile 30.97 (.27–3.44).961.64 (.77–3.50).20
 Quartile 41.001.00
P value for trend.02.03
Total lycopene
 Quartile 13.56 (1.16–10.92).030.95 (.50–1.82).88
 Quartile 21.99 (.65–6.13).230.90 (.46–1.76).76
 Quartile 32.41 (.71–8.20).160.66 (.33–1.32).24
 Quartile 41.001.00
P value for trend.04.88
α-Carotene
 Quartile 14.54 (1.26–16.32).021.00 (.49–2.03)1.00
 Quartile 21.83 (.53–6.30).341.60 (.81–3.15).17
 Quartile 31.93 (.55–6.75).310.80 (.38–1.68).55
 Quartile 41.001.00
P value for trend.03.55
Total β-carotene
 Quartile 12.58 (.82–8.07).101.18 (.58–2.39).66
 Quartile 22.51 (.76–8.32).130.97 (.48–1.95).92
 Quartile 30.98 (.27–3.48).971.14 (.59–2.24).69
 Quartile 41.001.00
P value for trend.05.77
Micronutrient Levels by QuartileaAge 10–19 yAge ≥ 20 y
Multivariate ORb (95% CI) (n = 237)P ValueMultivariate ORb (95% CI) (n = 565)P Value
Vitamin A <200 µg/L18.58 (3.54–97.60).00110.21 (2.43–42.91).002
Vitamin A level
 Quartile 17.72 (2.06–28.91).0024.43 (1.83–10.73).001
 Quartile 24.83 (1.23–18.92).023.50 (1.46–8.40).005
 Quartile 31.001.65 (.70–3.88).25
 Quartile 4NAc1.00
P value for trend.003<.001
Lutein + zeaxanthin
 Quartile 11.68 (.59–4.76).331.61 (.78–3.31).19
 Quartile 21.09 (.37–3.20).881.41 (.67–2.96).37
 Quartile 30.33 (.08–1.33).122.05 (1.01–4.17).05
 Quartile 41.001.00
P value for trend.12.24
β-Cryptoxanthin
 Quartile 14.39 (1.33–14.46).012.00 (.95–4.25).07
 Quartile 21.57 (.46–5.34).472.02 (1.00–4.08).05
 Quartile 30.97 (.27–3.44).961.64 (.77–3.50).20
 Quartile 41.001.00
P value for trend.02.03
Total lycopene
 Quartile 13.56 (1.16–10.92).030.95 (.50–1.82).88
 Quartile 21.99 (.65–6.13).230.90 (.46–1.76).76
 Quartile 32.41 (.71–8.20).160.66 (.33–1.32).24
 Quartile 41.001.00
P value for trend.04.88
α-Carotene
 Quartile 14.54 (1.26–16.32).021.00 (.49–2.03)1.00
 Quartile 21.83 (.53–6.30).341.60 (.81–3.15).17
 Quartile 31.93 (.55–6.75).310.80 (.38–1.68).55
 Quartile 41.001.00
P value for trend.03.55
Total β-carotene
 Quartile 12.58 (.82–8.07).101.18 (.58–2.39).66
 Quartile 22.51 (.76–8.32).130.97 (.48–1.95).92
 Quartile 30.98 (.27–3.48).971.14 (.59–2.24).69
 Quartile 41.001.00
P value for trend.05.77

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio.

aQuartile 1 is the lowest, and quartile 4 the highest. All levels were measured in micrograms per liter.

bAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, and index patient smear status.

cCategorized into tertiles because there were ≤5 case patients in the highest quartile.

Table 6.

Micronutrient Levels and Risk of Tuberculosis Disease Stratified by Age Category

Micronutrient Levels by QuartileaAge 10–19 yAge ≥ 20 y
Multivariate ORb (95% CI) (n = 237)P ValueMultivariate ORb (95% CI) (n = 565)P Value
Vitamin A <200 µg/L18.58 (3.54–97.60).00110.21 (2.43–42.91).002
Vitamin A level
 Quartile 17.72 (2.06–28.91).0024.43 (1.83–10.73).001
 Quartile 24.83 (1.23–18.92).023.50 (1.46–8.40).005
 Quartile 31.001.65 (.70–3.88).25
 Quartile 4NAc1.00
P value for trend.003<.001
Lutein + zeaxanthin
 Quartile 11.68 (.59–4.76).331.61 (.78–3.31).19
 Quartile 21.09 (.37–3.20).881.41 (.67–2.96).37
 Quartile 30.33 (.08–1.33).122.05 (1.01–4.17).05
 Quartile 41.001.00
P value for trend.12.24
β-Cryptoxanthin
 Quartile 14.39 (1.33–14.46).012.00 (.95–4.25).07
 Quartile 21.57 (.46–5.34).472.02 (1.00–4.08).05
 Quartile 30.97 (.27–3.44).961.64 (.77–3.50).20
 Quartile 41.001.00
P value for trend.02.03
Total lycopene
 Quartile 13.56 (1.16–10.92).030.95 (.50–1.82).88
 Quartile 21.99 (.65–6.13).230.90 (.46–1.76).76
 Quartile 32.41 (.71–8.20).160.66 (.33–1.32).24
 Quartile 41.001.00
P value for trend.04.88
α-Carotene
 Quartile 14.54 (1.26–16.32).021.00 (.49–2.03)1.00
 Quartile 21.83 (.53–6.30).341.60 (.81–3.15).17
 Quartile 31.93 (.55–6.75).310.80 (.38–1.68).55
 Quartile 41.001.00
P value for trend.03.55
Total β-carotene
 Quartile 12.58 (.82–8.07).101.18 (.58–2.39).66
 Quartile 22.51 (.76–8.32).130.97 (.48–1.95).92
 Quartile 30.98 (.27–3.48).971.14 (.59–2.24).69
 Quartile 41.001.00
P value for trend.05.77
Micronutrient Levels by QuartileaAge 10–19 yAge ≥ 20 y
Multivariate ORb (95% CI) (n = 237)P ValueMultivariate ORb (95% CI) (n = 565)P Value
Vitamin A <200 µg/L18.58 (3.54–97.60).00110.21 (2.43–42.91).002
Vitamin A level
 Quartile 17.72 (2.06–28.91).0024.43 (1.83–10.73).001
 Quartile 24.83 (1.23–18.92).023.50 (1.46–8.40).005
 Quartile 31.001.65 (.70–3.88).25
 Quartile 4NAc1.00
P value for trend.003<.001
Lutein + zeaxanthin
 Quartile 11.68 (.59–4.76).331.61 (.78–3.31).19
 Quartile 21.09 (.37–3.20).881.41 (.67–2.96).37
 Quartile 30.33 (.08–1.33).122.05 (1.01–4.17).05
 Quartile 41.001.00
P value for trend.12.24
β-Cryptoxanthin
 Quartile 14.39 (1.33–14.46).012.00 (.95–4.25).07
 Quartile 21.57 (.46–5.34).472.02 (1.00–4.08).05
 Quartile 30.97 (.27–3.44).961.64 (.77–3.50).20
 Quartile 41.001.00
P value for trend.02.03
Total lycopene
 Quartile 13.56 (1.16–10.92).030.95 (.50–1.82).88
 Quartile 21.99 (.65–6.13).230.90 (.46–1.76).76
 Quartile 32.41 (.71–8.20).160.66 (.33–1.32).24
 Quartile 41.001.00
P value for trend.04.88
α-Carotene
 Quartile 14.54 (1.26–16.32).021.00 (.49–2.03)1.00
 Quartile 21.83 (.53–6.30).341.60 (.81–3.15).17
 Quartile 31.93 (.55–6.75).310.80 (.38–1.68).55
 Quartile 41.001.00
P value for trend.03.55
Total β-carotene
 Quartile 12.58 (.82–8.07).101.18 (.58–2.39).66
 Quartile 22.51 (.76–8.32).130.97 (.48–1.95).92
 Quartile 30.98 (.27–3.48).971.14 (.59–2.24).69
 Quartile 41.001.00
P value for trend.05.77

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio.

aQuartile 1 is the lowest, and quartile 4 the highest. All levels were measured in micrograms per liter.

bAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, and index patient smear status.

cCategorized into tertiles because there were ≤5 case patients in the highest quartile.

To rule out the possibility that VAD in case patients may have resulted from metabolic derangements due to early active tuberculosis disease that was not clinically apparent, we stratified by baseline infection status and found that vitamin A levels remained strongly associated with tuberculosis disease in both groups (Table 7). In a second sensitivity analysis excluding case patients (and their matched controls) with disease diagnosed within 90 days of index patient enrollment, multivariable analysis also showed a strong inverse association between quartiles of vitamin A and tuberculosis disease, although the association with VAD was no longer statistically significant (Table 7).

Table 7.

Vitamin A Levels and Risk of Tuberculosis Disease Stratified by Baseline Infection Status and for Tuberculosis Diagnosed ≥90 Days After Enrollment of Index Case Patients

Vitamin A Levels by Tuberculosis StatusCase Patients, No./Controls, No.Multivariate ORb (95% CI)P Value
Negative for tuberculosis infection at baseline
 Vitamin A
  Quartile 112/1064.38 (1.24–15.47).02
  Quartile 213/1443.71 (1.12–12.33).03
  Quartile 36/1521.00
  Quartile 4NAc
  P value for trend.02
 VAD (level <200 µg/L)3/820.32 (2.91–141.70).002
Positive for tuberculosis infection at baseline
 Vitamin A
  Quartile 180/902.56 (1.17–5.58).02
  Quartile 240/891.83 (.85–3.92).12
  Quartile 325/1021.00
  Quartile 4NA
  P value for trend.02
 VAD (level <200 µg/L)21/85.31 (1.63–17.25).01
Tuberculosis diagnosed ≥90 d after enrollment of index case patients
 Vitamin A
  Quartile 127/704.21 (1.20–14.74)0.02
  Quartile 224/735.25 (1.44–19.10)0.01
  Quartile 319/792.91 (.87–9.77)0.08
  Quartile 48/891.00
  P value for trend .02
 VAD (level <200 µg/L)3/82.15 (.33–13.80).42
Vitamin A Levels by Tuberculosis StatusCase Patients, No./Controls, No.Multivariate ORb (95% CI)P Value
Negative for tuberculosis infection at baseline
 Vitamin A
  Quartile 112/1064.38 (1.24–15.47).02
  Quartile 213/1443.71 (1.12–12.33).03
  Quartile 36/1521.00
  Quartile 4NAc
  P value for trend.02
 VAD (level <200 µg/L)3/820.32 (2.91–141.70).002
Positive for tuberculosis infection at baseline
 Vitamin A
  Quartile 180/902.56 (1.17–5.58).02
  Quartile 240/891.83 (.85–3.92).12
  Quartile 325/1021.00
  Quartile 4NA
  P value for trend.02
 VAD (level <200 µg/L)21/85.31 (1.63–17.25).01
Tuberculosis diagnosed ≥90 d after enrollment of index case patients
 Vitamin A
  Quartile 127/704.21 (1.20–14.74)0.02
  Quartile 224/735.25 (1.44–19.10)0.01
  Quartile 319/792.91 (.87–9.77)0.08
  Quartile 48/891.00
  P value for trend .02
 VAD (level <200 µg/L)3/82.15 (.33–13.80).42

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; VAD, vitamin A deficiency.

aQuartile 1 is the lowest, and quartile 4 the highest. All levels were measured in micrograms per liter.

bAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, and index patient smear status.

cCategorized into tertiles because there were ≤5 case patients in the highest quartile.

Table 7.

Vitamin A Levels and Risk of Tuberculosis Disease Stratified by Baseline Infection Status and for Tuberculosis Diagnosed ≥90 Days After Enrollment of Index Case Patients

Vitamin A Levels by Tuberculosis StatusCase Patients, No./Controls, No.Multivariate ORb (95% CI)P Value
Negative for tuberculosis infection at baseline
 Vitamin A
  Quartile 112/1064.38 (1.24–15.47).02
  Quartile 213/1443.71 (1.12–12.33).03
  Quartile 36/1521.00
  Quartile 4NAc
  P value for trend.02
 VAD (level <200 µg/L)3/820.32 (2.91–141.70).002
Positive for tuberculosis infection at baseline
 Vitamin A
  Quartile 180/902.56 (1.17–5.58).02
  Quartile 240/891.83 (.85–3.92).12
  Quartile 325/1021.00
  Quartile 4NA
  P value for trend.02
 VAD (level <200 µg/L)21/85.31 (1.63–17.25).01
Tuberculosis diagnosed ≥90 d after enrollment of index case patients
 Vitamin A
  Quartile 127/704.21 (1.20–14.74)0.02
  Quartile 224/735.25 (1.44–19.10)0.01
  Quartile 319/792.91 (.87–9.77)0.08
  Quartile 48/891.00
  P value for trend .02
 VAD (level <200 µg/L)3/82.15 (.33–13.80).42
Vitamin A Levels by Tuberculosis StatusCase Patients, No./Controls, No.Multivariate ORb (95% CI)P Value
Negative for tuberculosis infection at baseline
 Vitamin A
  Quartile 112/1064.38 (1.24–15.47).02
  Quartile 213/1443.71 (1.12–12.33).03
  Quartile 36/1521.00
  Quartile 4NAc
  P value for trend.02
 VAD (level <200 µg/L)3/820.32 (2.91–141.70).002
Positive for tuberculosis infection at baseline
 Vitamin A
  Quartile 180/902.56 (1.17–5.58).02
  Quartile 240/891.83 (.85–3.92).12
  Quartile 325/1021.00
  Quartile 4NA
  P value for trend.02
 VAD (level <200 µg/L)21/85.31 (1.63–17.25).01
Tuberculosis diagnosed ≥90 d after enrollment of index case patients
 Vitamin A
  Quartile 127/704.21 (1.20–14.74)0.02
  Quartile 224/735.25 (1.44–19.10)0.01
  Quartile 319/792.91 (.87–9.77)0.08
  Quartile 48/891.00
  P value for trend .02
 VAD (level <200 µg/L)3/82.15 (.33–13.80).42

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; VAD, vitamin A deficiency.

aQuartile 1 is the lowest, and quartile 4 the highest. All levels were measured in micrograms per liter.

bAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, and index patient smear status.

cCategorized into tertiles because there were ≤5 case patients in the highest quartile.

Restricting the analysis to microbiologically confirmed cases further strengthened the association between vitamin A levels and tuberculosis disease (Table 8). We were unable to stratify by IPT use because few HHCs had received IPT.

Table 8.

Vitamin A Levels and Risk of Microbiologically Confirmed Tuberculosis Disease

Vitamin A LevelsaAll ParticipantsAge 10–19 yAge ≥20 y
Multivariate ORb (95% CI) (n = 666)P ValueMultivariate ORb (95% CI) (n = 178)P ValueMultivariate ORb (95% CI) (n = 487)P Value
Quartile 17.51 (2.75–20.54)<.0018.30 (1.82–37.86).016.95 (2.44–19.79)<.001
Quartile 25.71 (2.22–14.67)<.0012.56 (.49–13.52).274.97 (1.89–13.07).001
Quartile 33.58 (1.40–9.19)0.011.001.60 (.59–4.29).35
Quartile 41.00NAc1.00
P value for trend<.001.002<.001
VAD (level <200 µg/L)16.65 (5.36–51.77)<.00121.41 (3.71–123.48).00116.23 (3.12–84.44)<.001
Vitamin A LevelsaAll ParticipantsAge 10–19 yAge ≥20 y
Multivariate ORb (95% CI) (n = 666)P ValueMultivariate ORb (95% CI) (n = 178)P ValueMultivariate ORb (95% CI) (n = 487)P Value
Quartile 17.51 (2.75–20.54)<.0018.30 (1.82–37.86).016.95 (2.44–19.79)<.001
Quartile 25.71 (2.22–14.67)<.0012.56 (.49–13.52).274.97 (1.89–13.07).001
Quartile 33.58 (1.40–9.19)0.011.001.60 (.59–4.29).35
Quartile 41.00NAc1.00
P value for trend<.001.002<.001
VAD (level <200 µg/L)16.65 (5.36–51.77)<.00121.41 (3.71–123.48).00116.23 (3.12–84.44)<.001

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; VAD, vitamin A deficiency.

aQuartile 1 is the lowest, and quartile 4 the highest. Vitamin A levels were measured in micrograms per liter.

bAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, and index patient smear status.

cCategorized into tertiles because there were ≤5 case patients in the highest quartile.

Table 8.

Vitamin A Levels and Risk of Microbiologically Confirmed Tuberculosis Disease

Vitamin A LevelsaAll ParticipantsAge 10–19 yAge ≥20 y
Multivariate ORb (95% CI) (n = 666)P ValueMultivariate ORb (95% CI) (n = 178)P ValueMultivariate ORb (95% CI) (n = 487)P Value
Quartile 17.51 (2.75–20.54)<.0018.30 (1.82–37.86).016.95 (2.44–19.79)<.001
Quartile 25.71 (2.22–14.67)<.0012.56 (.49–13.52).274.97 (1.89–13.07).001
Quartile 33.58 (1.40–9.19)0.011.001.60 (.59–4.29).35
Quartile 41.00NAc1.00
P value for trend<.001.002<.001
VAD (level <200 µg/L)16.65 (5.36–51.77)<.00121.41 (3.71–123.48).00116.23 (3.12–84.44)<.001
Vitamin A LevelsaAll ParticipantsAge 10–19 yAge ≥20 y
Multivariate ORb (95% CI) (n = 666)P ValueMultivariate ORb (95% CI) (n = 178)P ValueMultivariate ORb (95% CI) (n = 487)P Value
Quartile 17.51 (2.75–20.54)<.0018.30 (1.82–37.86).016.95 (2.44–19.79)<.001
Quartile 25.71 (2.22–14.67)<.0012.56 (.49–13.52).274.97 (1.89–13.07).001
Quartile 33.58 (1.40–9.19)0.011.001.60 (.59–4.29).35
Quartile 41.00NAc1.00
P value for trend<.001.002<.001
VAD (level <200 µg/L)16.65 (5.36–51.77)<.00121.41 (3.71–123.48).00116.23 (3.12–84.44)<.001

Abbreviations: CI, confidence interval; NA, not applicable; OR, odds ratio; VAD, vitamin A deficiency.

aQuartile 1 is the lowest, and quartile 4 the highest. Vitamin A levels were measured in micrograms per liter.

bAdjusted for matching factors (age and sex), body mass index categories, socioeconomic status, heavy alcohol consumption, tobacco use, isoniazid preventive therapy, tuberculosis history, comorbid disease, self-reported diabetes mellitus, and index patient smear status.

cCategorized into tertiles because there were ≤5 case patients in the highest quartile.

DISCUSSION

In the current study, we found that vitamin A levels strongly predict progression to tuberculosis disease in a cohort of Peruvians with household exposure to an index patient with tuberculosis. This relationship remained strong after adjustment for socioeconomic status, BMI, and other comorbid conditions that might be associated with increased tuberculosis disease risk and lower vitamin A levels. Although the association is most extreme at levels consistent with a diagnosis of VAD, we observed a dose-response relationship with significantly increased risk of tuberculosis disease, even at vitamin A levels usually classified as normal. Carotenoids were also inversely associated with risk of tuberculosis progression among adolescents, although the effect of individual carotenoids was less extreme than for vitamin A.

Although multiple previous studies have documented low vitamin A levels among patients with an active tuberculosis diagnosis [8, 9, 29, 30], the causal direction of this association has been difficult to determine. Active tuberculosis disease can lead to profound weight loss and metabolic disturbances, and the micronutrient deficiencies observed in patients often improve or resolve with successful tuberculosis treatment [30]. To date, to our knowledge, no published studies have reported on the impact of vitamin A supplementation on incident tuberculosis disease, and clinical trials have demonstrated little impact of supplementation on tuberculosis treatment outcomes [30].

In contrast to the plethora of work on micronutrients and tuberculosis treatment outcomes [30], few studies have prospectively investigated the role of preexisting vitamin A status in the development of tuberculosis disease. Cegielski et al [14] observed that <2% of the US-based National Health and Nutrition Examination Survey 1 cohort had baseline vitamin A levels <300 µg/L (<1.05 µmol/L), and tuberculosis disease developed in only 61 persons during 20 years of follow-up. Although tuberculosis incidence was nearly 3-fold higher among those with low vitamin A levels, CIs for the hazard ratio ranged from .70 to 11.4. These results are consistent with findings from a study conducted in Philadelphia between 1942 and 1949, in which African American men with low baseline vitamin A levels were 3 times more likely to develop tuberculosis disease than those with higher levels [15]. Interestingly, the mean vitamin A level was 300 µg/L (1.05 µmol/L), suggesting that the comparison was between men with low and very low levels, rather than among persons with the spectrum of levels we observed in Lima.

This study also found a very strong effect of vitamin C deficiency; all in whom tuberculosis disease developed had baseline vitamin C levels <6 mg/L (<34.07 µmol/L). Our findings are also consistent with those of a recent study that evaluated role of vitamin A in tuberculosis disease progression among HIV-infected patients. In a cohort of HIV-infected patients from low- and middle-income countries, Tenforde et al [31] found that VAD, before initiation of antiretroviral therapy, conferred a 5-fold increase in the risk of incident tuberculosis disease.

Multiple other lines of evidence suggest an association between vitamin A levels and tuberculosis risk. In vitro studies have demonstrated that vitamin A and its metabolites cause dose-dependent inhibition of Mycobacterium tuberculosis growth in culture [32, 33]. Experimental studies in animal and cell models of tuberculosis infection also provide support for the protective role of retinol. Although early studies in various models gave conflicting results [34–36], more recent studies in mice [37], rats [38], THP-1 cells [39], and cultured human macrophages [40] have shown reduced M. tuberculosis bacillary loads after treatment with retinoic acid. Interestingly, the dose of retinoic acid required to produce a protective effect in human macrophages is lower when it was added before infection than when it was added afterward [40].

Vitamin A also affects the immune system in various ways relevant to the pathogenesis of tuberculosis [41–43]. Most of its effects are exerted by retinoic acid, which binds to the nuclear receptors RAR and RXR to control transcriptional expression of numerous target genes. Among its recently recognized effects on immunity, retinol modulates the maturation, antigen presentation, migration, and T-cell priming functions of dendritic cells [44–46], as well as the generation of T-regulatory cells and suppression of T-helper 17 cells [47]. Retinoic acid has also been shown to be crucial to the maintenance of the T-helper 1 lineage [48], an essential component of an effective immune response to tuberculosis.

In addition to its impact on acquired immunity, vitamin A may also play a role in innate immune responses to M. tuberculosis. Wheelwright et al [6] found that all-trans-retinoic acid exerts an antimicrobial effect on M. tuberculosis in human monocytes through its effect on cellular cholesterol efflux mediated through the NPC2 gene. Stimulation of primary human monocytes with all-trans-retinoic acid increased expression of NPC2 and reduced cellular cholesterol through a mechanism distinct from the antimicrobial activity of 1,25-dihydroxyvitamin D3 [7]. M. tuberculosis has been shown to use host lipids as a nutrient source, and host cholesterol mediates M. tuberculosis persistence and survival within macrophages [49]. Taken together, these findings suggest that low vitamin A levels may impair the host’s ability to control tuberculosis infection after exposure.

Carotenoids are naturally occurring pigments in fruits and vegetables, and 2 studies previously reported decreased tuberculosis risk among children and adult smokers with high intake of fruits and vegetables [50, 51]. To our knowledge, only 1 prior study has evaluated the association between carotenoid levels and incident tuberculosis; in that study, baseline total carotenoid levels in HIV-positive patients receiving antiretroviral therapy were not associated with an increased risk of tuberculosis disease [31].

Our study had notable limitations. Participants were followed up for 1 year, a relatively short period of time, given the slow pathogenesis of tuberculosis. Because we had relatively few blood samples from children aged <10 years, we were unable to assess the impact of VAD in that age group. Almost all our study participants had been vaccinated with BCG, so we are unable to distinguish between the possibilities that vitamin A enhanced BCG-induced adaptive immunity or provided direct protection against tuberculosis progression. Although we found no evidence of an interaction between vitamin A and vitamin D on tuberculosis disease risk, our study may not have been powered to detect such an interaction.

Prior studies have found that acute infections, such as pneumonia and rotavirus, temporarily reduce serum vitamin A levels [52, 53]. It is possible that HHCs recently infected with tuberculosis also experienced a reduction in retinol levels, and that process may explain our findings. A reduction in serum retinol levels during tuberculosis infection has not been observed in human studies to date, but this may be because it is challenging to determine exactly when individuals become infected with tuberculosis and to measure physiological changes occurring with that process.

Despite our efforts to ensure that nutritional assessments occurred before the development of tuberculosis disease, we could not rule out the possibility that participants had unrecognized tuberculosis disease at baseline, which may have led to the low retinol levels we observed. We addressed this issue by conducting 2 sensitivity analyses, the first stratified on baseline infection status and the second excluded cases diagnosed within 90 days of index patient enrollment. In both analyses, the risk of tuberculosis disease remained inversely associated with vitamin A quartiles regardless of baseline tuberculosis infection status or timing of diagnosis. Because active tuberculosis may remain clinically undetected for months, especially in children, there is no way to rule out reverse causality without conducting a clinical trial of vitamin A supplementation in persons at high risk for tuberculosis.

In conclusion, we find that vitamin A levels among persons exposed at home to a patient with tuberculosis strongly predicted incident tuberculosis disease within 12 months of follow-up, in a dose-dependent manner. Our data raise the possibility that screening for vitamin A levels among persons at high risk for tuberculosis could help identify those in whom disease is likely to develop in the near future so they could be targeted for early intervention. In the event that the association between VAD and tuberculosis progression proves to be causal, routine vitamin A supplementation among persons at high risk for tuberculosis disease (eg, HHCs of tuberculosis case patients or individuals in congregate settings, such as prisons) may provide an inexpensive, safe, and effective means of preventing progression from tuberculosis infection to tuberculosis disease.

Notes

Financial support. This work was supported by the National Institute of Allergy and Infectious Diseases (grants U19 AI076217 to M. B. M and U01 AI057786 to M. C. B); the National Institutes of Health (training grant T32DA013911 to O. A), and the National Institute of Mental Health–The Brown Initiative in HIV and AIDS Clinical Research for Minority Communities (grant 5R25MH083620 to O. A).

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

1.

World Health Organization (WHO)
.
Global Tuberculosis Report
.
Geneva, Switzerland
:
World Health Organization
,
2016
. Available at: http://www.who.int/tb/publications/global_report/en/ Accessed
20 October 2016
.

2.

McKeown
T
,
Record
RG
.
Reasons for the decline of mortality in England and Wales during the nineteenth century
.
Popul Stud
1962
;
16
:
94
122
.

3.

Janssens
JP
,
Rieder
HL
.
An ecological analysis of incidence of tuberculosis and per capita gross domestic product
.
Eur Respir J
2008
;
32
:
1415
6
.

4.

Dye
C
,
Lönnroth
K
,
Jaramillo
E
,
Williams
BG
,
Raviglione
M
.
Trends in tuberculosis incidence and their determinants in 134 countries
.
Bull World Health Organ
2009
;
87
:
683
91
.

5.

Cegielski
JP
,
McMurray
DN
.
The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals
.
Int J Tuberc Lung Dis
2004
;
8
:
286
98
.

6.

Wheelwright
M
,
Kim
EW
,
Inkeles
MS
et al.
All-trans retinoic acid-triggered antimicrobial activity against Mycobacterium tuberculosis is dependent on NPC2
.
J Immunol
2014
;
192
:
2280
90
.

7.

Liu
PT
,
Stenger
S
,
Li
H
et al.
Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response
.
Science
2006
;
311
:
1770
3
.

8.

van Lettow
M
,
Harries
AD
,
Kumwenda
JJ
et al.
Micronutrient malnutrition and wasting in adults with pulmonary tuberculosis with and without HIV co-infection in Malawi
.
BMC Infect Dis
2004
;
4
:
61
.

9.

Srinivasan
A
,
Syal
K
,
Banerjee
D
et al.
Low plasma levels of cholecalciferol and 13-cis-retinoic acid in tuberculosis: implications in host-based chemotherapy
.
Nutrition
2013
;
29
:
1245
51
.

10.

Nnoaham
KE
,
Clarke
A
.
Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis
.
Int J Epidemiol
2008
;
37
:
113
9
.

11.

Sudfeld
CR
,
Giovannucci
EL
,
Isanaka
S
et al.
Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected Tanzanian adults initiating antiretroviral therapy
.
J Infect Dis
2013
;
207
:
378
85
.

12.

Talat
N
,
Perry
S
,
Parsonnet
J
,
Dawood
G
,
Hussain
R
.
Vitamin D deficiency and tuberculosis progression
.
Emerg Infect Dis
2010
;
16
:
853
5
.

13.

Arnedo-Pena
A
,
Juan-Cerdán
JV
,
Romeu-García
A
et al.
Vitamin D status and incidence of tuberculosis among contacts of pulmonary tuberculosis patients
.
Int J Tuberc Lung Dis
2015
;
19
:
65
69
.

14.

Cegielski
JP
,
Arab
L
,
Cornoni-Huntley
J
.
Nutritional risk factors for tuberculosis among adults in the United States, 1971–1992
.
Am J Epidemiol
2012
;
176
:
409
22
.

15.

Getz
HR
,
Long
ER
,
Henderson
HJ
.
A study of the relation of nutrition to the development of tuberculosis; influence of ascorbic acid and vitamin A
.
Am Rev Tuberc
1951
;
64
:
381
93
.

16.

Green
HN
,
Mellanby
E
.
Vitamin A as an anti-infective agent
.
Br Med J
1928
;
2
:
691
6
.

17.

Mellanby
E
,
Green
HN
.
Vitamin A as an anti-infective agent: its use in the treatment of puerperal septigaemia
.
Br Med J
1929
;
1
:
984
6
.

18.

Green
HN
,
Pindar
D
,
Davis
G
,
Mellanby
E
.
Diet as a prophylactic agent against puerperal sepsis
.
Br Med J
1931
;
2
:
595
8
.

19.

Ellison
JB
.
Intensive vitamin therapy in measles
.
Br Med J
1932
;
2
:
708
11
.

20.

Stevens
GA
,
Bennett
JE
,
Hennocq
Q
et al.
Trends and mortality effects of vitamin A deficiency in children in 138 low-income and middle-income countries between 1991 and 2013: a pooled analysis of population-based surveys
.
Lancet Glob Health
2015
;
3
:
e528
36
.

21.

Peru Ministerio de Salud
. Norma técnica de salud para el control de la tuberculosis. Dirección general de salud de las personas. Estrategia sanitaria nacional de prevención y control de la tuberculosis.
2006
. Available at: ftp://ftp2.minsa.gob.pe/descargas/dgsp/ESN-tuberculosis/normaspublicaciones/NTSTBC.pdf Accessed 20 June 2017.

22.

Graham
SM
,
Ahmed
T
,
Amanullah
F
et al.
Evaluation of tuberculosis diagnostics in children: 1. Proposed clinical case definitions for classification of intrathoracic tuberculosis disease. Consensus from an expert panel
.
J Infect Dis
2012
;
205
(
suppl 2
):
S199
208
.

23.

El–Sohemy
A
,
Baylin
A
,
Kabagambe
E
,
Ascherio
A
,
Spiegelman
D
,
Campos
H
.
Individual carotenoid concentrations in adipose tissue and plasma as biomarkers of dietary intake
.
Am J Clin Nutr
,
2002
;
76
:
172
9
.

24.

Rice
AL
,
West
KP
Jr
,
Black
RE
.
Vitamin A deficiency: global and regional burden of disease attributable to selected major risk factors
.
Vol 1
. Chapter 4.
World Health Organization
,
2004
. Available at: http://www.who.int/publications/cra/chapters/volume1/0211-0256.pdf?ua=1 Accessed 20 June 2017.

25.

Institute of Medicine
.
Dietary reference intakes for calcium and vitamin D
.
Washington, DC
:
National Academies Press
,
2011
.

26.

World Health Organization (WHO)
.
Child growth standards
.
2011
. Available from: http://www.who.int/childgrowth/software/en/ Accessed 20 June 2017.

27.

Filmer
D
,
Pritchett
LH
.
Estimating wealth effects without expenditure data–or tears: an application to educational enrollments in states of India
.
Demography
2001
;
38
:
115
32
.

28.

Rothman
KJ
,
Greenland
S
,
Lash
TL
.
Modern epidemiology
. 3rd ed.
Philadelphia, PA
:
Lippincott, Williams & Wilkins
,
2008
.

29.

Karyadi
E
,
Schultink
W
,
Nelwan
RH
et al.
Poor micronutrient status of active pulmonary tuberculosis patients in Indonesia
.
J Nutr
2000
;
130
:
2953
8
.

30.

Sinclair
D
,
Abba
K
,
Grobler
L
,
Sudarsanam
TD
.
Nutritional supplements for people being treated for active tuberculosis
.
Cochrane Database Syst Rev
2011
;
11
:
CD006086
.

31.

Tenforde
MW
,
Yadav
A
,
Dowdy
DW
et al.
Vitamin A and D deficiencies associated with incident tuberculosis in HIV-infected patients initiating antiretroviral therapy in a multinational case-cohort study
.
J Acquir Immune Defic Syndr
2017
; 75:e71–9. doi:
10.1097/QAI.0000000000001308
.

32.

Greenstein
RJ
,
Su
L
,
Brown
ST
.
Vitamins A & D inhibit the growth of mycobacteria in radiometric culture
.
PLoS One
2012
;
7
:
e29631
.

33.

Greenstein
RJ
,
Su
L
,
Shahidi
A
,
Brown
WD
,
Clifford
A
,
Brown
ST
.
Unanticipated Mycobacterium tuberculosis complex culture inhibition by immune modulators, immune suppressants, a growth enhancer, and vitamins A and D: clinical implications
.
Int J Infect Dis
2014
;
26
:
37
43
.

34.

Finkelstein
MH
.
Effect of carotene on course of B. tuberculosis infection of mice fed on a vitamin A deficient diet
.
Exp Biol Med (Maywood)
1932
;
29
:
969
71
.

35.

Solotorovsky
M
,
Squibb
RL
,
Wogan
GN
,
Siegel
H
,
Gala
H
.
The effect of dietary fat and vitamin A on avian tuberculosis in chicks
.
Am Rev Respir Dis
1961
;
84
:
226
35
.

36.

Gloyne
SR
,
Page
DS
.
A preliminary note on the relationship between deficiency in vitamin A and tuberculosis
.
Tubercle
1921
;
3
:
577
9
.

37.

Layton
HW
,
Youmans
GP
.
Effect of dietary factors upon the resistance of albino mice to experimental infection with Mycobacterium tuberculosis
.
J Bacteriol
1965
;
90
:
958
64
.

38.

Yamada
H
,
Mizuno
S
,
Ross
AC
,
Sugawara
I
.
Retinoic acid therapy attenuates the severity of tuberculosis while altering lymphocyte and macrophage numbers and cytokine expression in rats infected with Mycobacterium tuberculosis
.
J Nutr
2007
;
137
:
2696
700
.

39.

Anand
PK
,
Kaul
D
.
Downregulation of TACO gene transcription restricts mycobacterial entry/survival within human macrophages
.
FEMS Microbiol Lett
2005
;
250
:
137
44
.

40.

Crowle
AJ
,
Ross
EJ
.
Inhibition by retinoic acid of multiplication of virulent tubercle bacilli in cultured human macrophages
.
Infect Immun
1989
;
57
:
840
4
.

41.

Larange
A
,
Cheroutre
H
.
Retinoic acid and retinoic acid receptors as pleiotropic modulators of the immune system
.
Annu Rev Immunol
2016
;
34
:
369
94
.

42.

Brown
CC
,
Noelle
RJ
.
Seeing through the dark: new insights into the immune regulatory functions of vitamin A
.
Eur J Immunol
2015
;
45
:
1287
95
.

43.

Guo
Y
,
Brown
C
,
Ortiz
C
,
Noelle
RJ
.
Leukocyte homing, fate, and function are controlled by retinoic acid
.
Physiol Rev
2015
;
95
:
125
48
.

44.

Geissmann
F
,
Revy
P
,
Brousse
N
et al.
Retinoids regulate survival and antigen presentation by immature dendritic cells
.
J Exp Med
2003
;
198
:
623
34
.

45.

Bakdash
G
,
Vogelpoel
LT
,
van Capel
TM
,
Kapsenberg
ML
,
de Jong
EC
.
Retinoic acid primes human dendritic cells to induce gut-homing, IL-10-producing regulatory T cells
.
Mucosal Immunol
2015
;
8
:
265
78
.

46.

Darmanin
S
,
Chen
J
,
Zhao
S
et al.
All-trans retinoic acid enhances murine dendritic cell migration to draining lymph nodes via the balance of matrix metalloproteinases and their inhibitors
.
J Immunol
2007
;
179
:
4616
25
.

47.

Mucida
D
,
Park
Y
,
Kim
G
et al.
Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid
.
Science
2007
;
317
:
256
60
.

48.

Brown
CC
,
Esterhazy
D
,
Sarde
A
et al.
Retinoic acid is essential for Th1 cell lineage stability and prevents transition to a Th17 cell program
.
Immunity
2015
;
42
:
499
511
.

49.

Pandey
AK
,
Sassetti
CM
.
Mycobacterial persistence requires the utilization of host cholesterol
.
Proc Natl Acad Sci U S A
2008
;
105
:
4376
80
.

50.

Franke
MF
,
del Castillo
H
,
Pereda
Y
et al.
Modifiable factors associated with tuberculosis disease in children: a case-control study
.
Pediatr Infect Dis J
2014
;
33
:
109
11
.

51.

Hemilä
H
,
Kaprio
J
,
Pietinen
P
,
Albanes
D
,
Heinonen
OP
.
Vitamin C and other compounds in vitamin C rich food in relation to risk of tuberculosis in male smokers
.
Am J Epidemiol
1999
;
150
:
632
41
.

52.

Stephensen
CB
,
Alvarez
JO
,
Kohatsu
J
,
Hardmeier
R
,
Kennedy
JI
Jr
,
Gammon
RB
Jr
.
Vitamin A is excreted in the urine during acute infection
.
Am J Clin Nutr
1994
;
60
:
388
92
.

53.

Alvarez
JO
,
Salazar-Lindo
E
,
Kohatsu
J
,
Miranda
P
,
Stephensen
CB
.
Urinary excretion of retinol in children with acute diarrhea
.
Am J Clin Nutr
1995
;
61
:
1273
6
.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected]